BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 16026694)

  • 1. Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy.
    Kellie SJ; Chaku J; Lockwood LR; O'Regan P; Waters KD; Wong CK;
    Eur J Cancer; 2005 Jul; 41(11):1588-96. PubMed ID: 16026694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.
    Kellie SJ; Wong CK; Pozza LD; Waters KD; Lockwood L; Mauger DC; White L
    Med Pediatr Oncol; 2002 Sep; 39(3):168-74. PubMed ID: 12210445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
    Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High dosage methotrexate in combination with "8 in 1" in therapy of pediatric grade III/IV brain tumors].
    Schwabe D; Gussetis E; Jacobi G; Gerein V; Kornhuber B
    Klin Padiatr; 1992; 204(2):72-7. PubMed ID: 1583854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
    Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
    Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.
    Rutkowski S; Bode U; Deinlein F; Ottensmeier H; Warmuth-Metz M; Soerensen N; Graf N; Emser A; Pietsch T; Wolff JE; Kortmann RD; Kuehl J
    N Engl J Med; 2005 Mar; 352(10):978-86. PubMed ID: 15758008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
    Saran F; Baumert BG; Creak AL; Warrington AP; Ashley S; Traish D; Brada M
    Pediatr Blood Cancer; 2008 Mar; 50(3):554-60. PubMed ID: 17941071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain magnetic resonance imaging after high-dose chemotherapy and radiotherapy for childhood brain tumors.
    Spreafico F; Gandola L; Marchianò A; Simonetti F; Poggi G; Adduci A; Clerici CA; Luksch R; Biassoni V; Meazza C; Catania S; Terenziani M; Musumeci R; Fossati-Bellani F; Massimino M
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1011-9. PubMed ID: 17904307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma.
    Taylor RE; Bailey CC; Robinson KJ; Weston CL; Ellison D; Ironside J; Lucraft H; Gilbertson R; Tait DM; Saran F; Walker DA; Pizer BL; Lashford LS; ;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1184-93. PubMed ID: 15001263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with medulloblastoma treated with carboplatin and etoposide before and after radiotherapy.
    Lopez-Aguilar E; Sepulveda-Vildosola AC; Rivera-Marquez H; Cerecedo-Diaz F; Santacruz-Castillo E; Valdez-Sanchez M; Arias-Gomez J; Quintana-Roldan G
    Arch Med Res; 1998; 29(4):313-7. PubMed ID: 9887549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.
    Verlooy J; Mosseri V; Bracard S; Tubiana AL; Kalifa C; Pichon F; Frappaz D; Chastagner P; Pagnier A; Bertozzi AI; Gentet JC; Sariban E; Rialland X; Edan C; Bours D; Zerah M; Le Gales C; Alapetite C; Doz F
    Eur J Cancer; 2006 Nov; 42(17):3004-14. PubMed ID: 16956759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
    Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
    J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.
    Chi SN; Gardner SL; Levy AS; Knopp EA; Miller DC; Wisoff JH; Weiner HL; Finlay JL
    J Clin Oncol; 2004 Dec; 22(24):4881-7. PubMed ID: 15611503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma.
    Osumi AK; Mclendon RE; Tien RD; Friedman HS; Graham M; Hockenberger B; Halperin EC; Oakes WJ
    Clin Neuropathol; 1994; 13(5):281-5. PubMed ID: 7805312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma.
    Fliessbach K; Urbach H; Helmstaedter C; Pels H; Glasmacher A; Kraus JA; Klockgether T; Schmidt-Wolf I; Schlegel U
    Arch Neurol; 2003 Apr; 60(4):563-8. PubMed ID: 12707070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
    Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
    J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
    Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy.
    Taylor RE; Bailey CC; Robinson KJ; Weston CL; Walker DA; Ellison D; Ironside J; Pizer BL; Lashford LS
    Eur J Cancer; 2005 Mar; 41(5):727-34. PubMed ID: 15763649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.